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Abstract
Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with
cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced
translocations (N = 27) and telomeric rearrangements (N= 15), both mainly observed in myeloid disorders; and unbalanced
non-telomeric rearrangements (N= 39), mainly observed in lymphoid proliferations and frequently associated with a highly
complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36
were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the
TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised
the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas
[follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without
t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric
rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or
result from chromosomal instability during oncogenesis.
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Introduction
Chromosomal band 1p36 is a cytogenetic band of 28 megabases
(Mb) located at the telomeric part of the short arm of chromosome
1. This region is primarily known for its constitutional deletions,
which lead to polyvisceral and polymorphic defects due to a
contiguous gene syndrome [1,2]. Non-homologous end-joining
repair (NHEJ) seems to play a major role in most constitutional
1p36 rearrangements [3]. Acquired 1p36 alterations are frequent
in various solid tumors, especially in neuroblastomas in which
deletions of 1p36 are commonly encountered and correlated with
an unfavorable outcome [4]. Loss of heterozygosity (LOH) of the
1p36 region, found in 20 to 40% of these tumors, suggests the
presence of one or more tumor suppressor genes. However, the
genes targeted by this prognostically relevant chromosomal
aberration remain unknown, raising the question of the possible
implication of micro-RNAs (miRNAs) [5,6].
1p36 alterations are recurrent in hematological malignancies
and present in various forms. The most frequent abnormalities in
both myeloid and lymphoid neoplasias are unbalanced chromo-
somal rearrangements, usually described as add(1)(p36) [7],
leading to terminal 1p36 deletions. However, other clonal rear-
rangements have been reported, including reciprocal transloca-
tions (35%), unbalanced rearrangements (58%) and deletions (7%)
[8]. Cytogenetic 1p36 rearrangements are frequent in non-
Hodgkin lymphomas (NHL) (12% of cases) [9], and 1p36 deletions
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are encountered in roughly 20% of follicular lymphomas (FL) and
correlated with poor outcome [10]. There are no data on the
frequency of 1p36 rearrangements in myeloid malignances.
As 1p36 alterations are frequent in both solid and hematological
tumors, common oncogenic mechanisms may be involved,
affecting tumor suppressor genes in the case of deletions,
oncogenes in the case of balanced translocations and a com-
bination of both in the case of unbalanced rearrangements. The
confirmed or putative tumor suppressor genes mapped to 1p36
[11] include CDK11A (CDC2L2) and CDK11B (p58 or CDC2L1)
[12], TNFRSF1B (TNFR2) [13], ID3 [14], NBL1 (DAN) [15], PAX7
[16], TP73 [17] and RUNX3 [18]. There are also oncogenes,
including SKI [19] and PRDM16 [20]. Other 1p36 genes, like
MDS2, are involved in chromosomal translocations in hematolog-
ical malignancies, but their role is still unknown [21].
Following the example of PRDM16, which we found to be
recurrently rearranged in 31/61 acute myeloid leukemias (AML)
and myelodysplastic syndromes (MDS) with cytogenetic 1p36
rearrangements (Duhoux FP et al, submitted manuscript), our aim
was to identify other recurrent rearrangements on 1p36. While
array-Comparative Genomic Hybridization (CGH) data have
already been published in certain hematological malignancies
[22], they did not focus on 1p36. Moreover, arrays are not the
preferred technique for the characterization of balanced and/or
telomeric rearrangements. We therefore decided to characterize a
series of 81 hematological malignancies using a contig of
approximately 120 bacterial artificial chromosomes (BAC) dis-
persed over 28 Mb [mean resolution of 250 kilobases (kB)] and 20
fosmids to study more precisely specific 1p36 loci.
Materials and Methods
Study material
Cytogenetic pellets from 81 patients with hematological
malignancies displaying 1p36 alterations not involving PRDM16
were included in the present study. They were collected from 18
different centers in the frame of a joint study of the Groupe
Francophone de Cytoge´ne´tique He´matologique (GFCH) and of
the Belgian Cytogenetic Group for Hematology and Oncology
(BCG-HO).
Ethics statement
The Ethics Committee of Saint-Luc Hospital approved this
study (2007/27-28-29). Such retrospective studies on tissue
samples, some of which were stored for many years, do not fall
under the scope of the Belgian law (2004) on experimental studies
in human beings. Experimentation on residual tissue already
stored, as it is the case in this protocol, is allowed if the Ethics
Committee gives a positive opinion. In this case, the Ethics
Committee waved the need for written patient consent and gave a
positive opinion to the investigator.
Conventional cytogenetic analysis
Karyotyping was performed on bone marrow, peripheral blood
or lymph nodes by the referring center following local procedures.
All karyotypes were reported according to ISCN 2009 [23] and
centrally reviewed twice according to the GFCH and BCG-HO
rules.
Fluorescence in situ hybridization (FISH)
Dual-color FISH was performed centrally (Brussels, Belgium) on
fixed nuclei and metaphases. Commercially available probes were
obtained from Abbott Molecular (Ottignies/Louvain-la-Neuve,
Belgium), Kreatech (Amsterdam, The Netherlands) and Dako
(Heverlee, Belgium). Sub-telomeric probe TelVysion 1p (Abbott
Molecular, Ottignies/Louvain-la-Neuve, Belgium) and pan-telo-
meric probe Star*FISH (Cambio, Cambridge, UK) were used in
selected cases. Specific BAC or fosmid probes selected from the
Ensembl (www.ensembl.org) or UCSC (genome.ucsc.edu) data-
bases were obtained from the BACPAC Resources Center at the
Children’s Hospital Oakland Research Institute, Oakland, CA,
USA. DNA extractions, labeling and hybridizations were
performed as previously reported [24]. All hybridized metaphases
were captured on a Zeiss Axioplan 2 microscope (Zeiss, Zaventem,
Belgium), and analyzed with the Isis software (Metasystems,
Altlussheim, Germany). Metaphase FISH, which was performed
in all cases, was complemented by interphase FISH (up to 200
nuclei per sample) in selected cases. In certain cases, the same
slides were reused up to 3 times (protocol available on request).
Cell lines for telomere length quantification
Using cell lines whose telomere length had been previously
quantified by Southern Blot-based TRF (Telomere Restriction
Fragment) (LB37 +/2 1.5 kb, HeLa +/2 2 kb, SW39 +/2
3.5 kb, LB23 +/2 5 kb, MG63 +/2 7 kb and MZ2 +/2 15 kb)
[25], we determined that the minimal telomere length that was
detectable with the pan-telomeric Star*FISH probe in our
hybridization conditions was of approximately 3.5 kb.
Single nucleotide polymorphism (SNP) arrays
A DNA sample from patient 142 was analyzed using the
GeneChip Human Mapping 250K NspI (Affymetrix Inc., Santa
Clara, CA, USA) according to manufacturer’s instructions. Data
acquisition was performed using the Genotyping Console version
4.1 (Affymetrix).
Results
Patients’ characteristics are described in Table S1. Among the
81 patients, there were 38 myeloid, 42 lymphoid and 1
undifferentiated hematological malignancy. 27 had balanced
translocations, 39 unbalanced rearrangements and 15 telomeric
rearrangements. The median age of the patients was relatively
similar between the 3 subgroups: 62 years in the group of balanced
translocations (range 4–81), 56 in the group of unbalanced
rearrangements (range 1–87) and 62 in the group of telomeric
rearrangements (range 13–77). There were 2 pediatric (,18 years)
cases in the balanced, 6 in the unbalanced and 2 in the telomeric
subgroups.
Balanced translocations
Among the 27 patients with balanced translocations, 18 had
myeloid malignancies [9 AML, 6 MDS, 1 chronic myelogenous
leukemia (CML), 1 polycythemia vera (PV) and 1 myelofibrosis
(MF)] and 9 lymphoid malignancies [3 B-cell precursor acute
lymphoblastic leukemias (ALL), 3 chronic lymphocytic leukemias
(CLL), 1 Burkitt-like lymphoma, 1 marginal zone lymphoma
(MZL) and 1 T-cell lymphoma (TCL)]. Results of FISH analysis
are depicted in Figure 1 and in Table S2.
In total, the breakpoints on 1p36 were spread over more than
25 Mb. In 8 cases, microdeletions of various sizes were detected
near the breakpoints, while in other cases the FISH pattern (split
within a BAC) suggested the absence of breakpoint-associated
microdeletions at a resolution of approximately 100 kb. Fourteen
different partner chromosomes were identified in the 20 cases in
which they were identifiable.
No obvious hotspot could be identified except for 2 recurring
breakpoints, defined as 2 or more cases harboring the same
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breakpoint. The first occurred within the TP73 locus, in which two
breakpoint patterns were observed (Figure 2): the breakpoint was
either between probes RP11-46F15 and RP5-1092A11 in patients
050 and 105, or within the latter probe in patients 008 and 141. In
patient 050, the BAC pattern on 9q22.2 suggested an involvement
of the CKS2 (a cell cycle regulator [26]), the SECISBP2 or the
SEMA4D locus. Due to lack of material, the partner locus of
patient 105 could not be identified. In patient 008, the partner
locus of TP73 was located in a 3 Mb region on 2q22. Finally, in
patient 141, there were 2 balanced translocations, both affecting
the TP73 locus, emphasizing that TP73 is a recurrent target of
1p36 alterations: in a first subclone, it was rearranged with a
region on 13q14.2 comprising the DLEU2 locus, while in a second
subclone, the partner of TP73 was located on 1p35.1 in a region
containing only the ZBTB8A and ZBTB8B loci.
The second recurrently involved region on 1p36 (patients 121
and 149), was found between probes RP11-56N19 and RP11-
929P4, an interval of 722 kb which contains, among others,
TNFRSF8 (a positive regulator of apoptosis) and TNFRSF1B. In
patient 149 (a MF), we identified the partner locus as HMGA2 on
12q14.3 using break-apart probes RP11-125M17 and RP11-
427K2, suggesting a novel partner locus on 1p36 for this multi-
partner gene whose disruption and aberrant expression has been
observed in various myeloid malignancies [27].
In addition, we found a novel partner locus on 1p36 for RUNX1
in a case of MDS (patient 118), as shown with break-apart probes
RP11-8P19 and RP11-12N9. In this latter case, the breakpoint on
1p36 was located in a region of 1.2 Mb between probes RP3-
465N24 and RP11-492M19. The known RUNX1 partner loci
PRDM16 [28]and YTHDF2 [29]on 1p36 and 1p35, respectively,
were excluded.
Unbalanced, non-telomeric rearrangements
The 39 patients with unbalanced rearrangements included
9 myeloid disorders (7 AML, 1 MDS and 1 CML), 29 lymphoid
malignancies [2 B-cell precursor ALL, 1 lymphoproliferative syn-
drome (LPS), 17 FL, 5 diffuse large B-cell lymphomas (DLBCL), 2
MZL, 1 T-cell ALL and 1 peripheral T-cell lymphomas (PTCL)]
and 1 acute undifferenciated leukemia (AUL). There were 27 B-cell
lymphoproliferations, of which 19 presented with t(14;18)(q32;q21)
(16 FL and 3 DLBCL). Results of FISH analysis are depicted in
Figure 3 and in Table S3.
The cytogenetic presentation was heterogeneous (Table S1).
Besides der(1)t(1;1)(p36;q12–22) (N= 10), the partner chromosome
could only be identified in 6 cases exhibiting 6 different chro-
mosomal partner regions. In all but one case, the unbalanced
rearrangement led to the deletion of the terminal portion of the
1p36 band and to the addition of supplementary material beyond
the breakpoint. The size of the 1p deletion ranged from 1.8 to
21 Mb. Out of the 39 cases, 19 had a breakpoint on 1p36
clustered in a region of 2.4 Mb between RP11-902J21 on 1p36.23
and RP11-420G9 on 1p36.22. Of these 19 above-mentioned
cases, 15 were derived from the B-cell lineage and 9 harbored a
t(14;18)(q32;q21). FISH in one case of FL transformed into a
DLBCL and lacking a t(14;18)(q32;q21) (case 142) showed a
der(1)t(1;6)(p36.22;p22.2) that resulted in a deletion of 1p36
telomeric to probe RP11-177N11 on 1p36.22 and a partial 6p
trisomy ranging from 6p22.2 to 6pter, as determined by GeneChip
Human Mapping 250K Array Set (data not shown).
Telomeric rearrangements
There were 15 patients with rearrangements located at the
extreme telomeric end of chromosomal band 1p36.33, as
identified with the sub-telomeric 1p probe and the pan-telomeric
probe. The additional chromosomal material was located (i)
telomerically to the canonical repetitive telomeric sequences on
the derivative chromosome 1p in at least 7 cases (Figure 4B), (ii)
between the sub-telomeric 1p region and the first 3.5 kb of the
repetitive telomeric region in 6 cases (Figure 4C), (iii) while in 2
further cases, the possible presence of intrachromosomal telomeric
repetitive sequences could not be assessed due to an insufficient
length of the additional material (Figure 4D). Eleven out of 15
patients from this subgroup had myeloid [5 AML, 2 MDS, 1 PV, 1
MF, 1 chronic eosinophilic leukemia (CEL) and 1 Fanconi’s
anemia (FA)] and 4/15 had lymphoid malignancies [1 B-cell ALL,
2 mantle cell lymphomas (MCL) and 1 TCL]. Although the bone
marrow was morphologically normal, the case of FA (patient 125)
had acquired a subclonal add(1)(p36) in addition to a previously
identified gain of the long arm of chromosome 1, suggesting the
clonal evolution towards a hematological malignancy. Results of
FISH analysis are depicted in Figure 4 and in Table S4.
Associated chromosomal aberrations
The identity of the partner chromosomes was heterogeneous in
the cases in which they could be identified. The rearrangement
affecting 1p36 was the only detected rearrangement in 12 cases.
They were mainly myeloid malignancies (only 1 CLL). A complex
karyotype ($3 abnormalities) was found in 19/27 (70%) balanced,
29/39 (74%) unbalanced and 8/15 (53%) telomeric rearrange-
ments. Very complex karyotypes ($5 abnormalities) were
observed in only 7/27 (26%) balanced rearrangements, while
they were observed in 20/39 (51%) unbalanced and 6/15 (40%)
telomeric rearrangements. Of note, among the 16 simple
karyotypes in the subgroups of unbalanced and telomeric
rearrangements, 5 were der(1)t(1;1)(p36;q12–22) (31%).
Discussion
Structural rearrangements at 1p36 are relatively frequent in
solid tumors [4] and in hematological malignancies [8], especially
in NHL [9,22,30,31,32]. We confirmed the heterogeneity of 1p36
rearrangements. We showed that the breakpoints on 1p36 are
more widely distributed than previously reported [8] [33] and
identified new loci of interest.
1p36 deletions are observed in myeloid malignancies. In our
series, there were AML and MDS in all 3 identified rearrangement
subgroups. Prior studies have shown a high proportion of allelic loss
on 1p in patients with MDS (13%) [34] and in patients with MDS
evolving into AML (30%) [35]. The 1p36 rearrangements in
myeloid disorders in our series were more frequently balanced and/
or telomeric than in lymphoid disorders, as well as more often
isolated, emphasizing the oncogenic relevance of the event on 1p36.
On the other hand, the complexity of unbalanced rearrangements
in lymphoid disorders may reflect genomic instability.
Figure 1. Balanced translocations. Each column represents a case, each line represents a BAC or fosmid probe. 1 Mb intervals on 1p36 are
represented at the same size. Diagnoses are highlighted in gold in myeloid cases and in light yellow in lymphoid cases. The results of the used BAC
probes are represented in unshadowed boxes, inferences are represented in shadowed boxes. Cells are painted green, if the probe hybridizes to the
der(1), blue if the probe hybridizes to another chromosome, purple if the probe is split between the der(1) and another chromosome, and red if the
probe is deleted. Additional details are available in Table S2.
doi:10.1371/journal.pone.0026311.g001
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It is suspected that the loss of tumor suppressor genes on 1p36
contributes to oncogenesis [36]. In our series, TP73, one of the
potential 1p36 candidate tumor suppressor genes in B-cell
lymphomas [37–38], was deleted in 35 out of 39 cases with
unbalanced non-telomeric rearrangements. The involvement of
the TP73 locus in 4 cases of balanced translocation in our series (3
myeloid and 1 lymphoid cases) might indicate that this gene is
targeted by at least some 1p36 rearrangements, as some balanced
translocations may lead to inactivation of tumor suppressor genes
[39], a mechanism that might have occurred in these cases.
Figure 2. TP73 rearrangements. Schematic representation of the position of BAC probes and loci of interest in patients 050, 008, 141 and 105
(patients with TP73 involvement), adapted from www.ensembl.org. Due to lack of material, the partner locus could not be determined in the case of
patient 105. Of note, in patients 050 and 105, given the FISH resolution, we could not rule out an involvement of the WRAP73 locus, which is a
member of the WD repeat family, involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene
regulation [53].
doi:10.1371/journal.pone.0026311.g002
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In addition to TP73 and PRDM16, recently shown to be
rearranged with various partner genes in myeloid as well as
lymphoid malignancies (Duhoux FP et al, submitted manuscript),
we identified 3 other interesting genes, likely involved in the
pathogenesis of hematological malignancies: PRKCZ, RERE and
AJAP1. PRKCZ and RERE were the only genes at the 1p36
breakpoint in 2 CLL patients, respectively in a t(1;4)(p36;q25) (case
015) and in an isolated t(1;13)(p36;q13) (case 014). While balanced
translocations in CLL are infrequent, their presence is an adverse
prognostic factor [40]. PRKCZ is a putative oncogene, as it encodes
a member of a family of serine/threonine kinases involved in
proliferation, differentiation and secretion [41], while RERE may
be a a putative tumor suppressor gene because of its involvement
in the control of cell survival [42] and because it is the most
centromeric locus disrupted in 3 cases of unbalanced rearrange-
ments (cases 044, 113 and 102, i.e. respectively 1 LPS, 1 AML and
1 FL).
AJAP1, a putative neuroblastoma tumor suppressor gene [43],
was the most centromeric disrupted gene in a case of T-cell ALL
(case 136) and in a case of MZL (case 052) with unbalanced
rearrangements. All the loci telomeric to RERE and AJAP1 tested
in these cases were deleted, raising questions about the role played
by these genes.
The common impact of unbalanced rearrangements may be the
terminal 1p36 deletion, as there was no obvious recurrent
chromosomal partner in these cases. It is therefore logical to look
for one or more candidate tumor suppressor gene(s) in the deleted
regions.
The minimal deleted region, deleted in all unbalanced cases but
one, is the terminal subtelomeric region of 1.8 Mb. Of note, a
relevant locus in the centromeric of this region is the purported
tumor suppressor gene CDK11B, a kinase gene essential for cell
cycle control shown to be deleted in NHL [12].
The TNFRSF14 locus on 1p36.32 (located at 2.4 Mb from the
1p telomere) was deleted in all our 18 cases of FL. This locus was
recently shown to be deleted or associated with LOH in 20% of
FL, and these alterations were associated with worse prognosis.
The residual allele was affected by nonsynonymous mutations in 3
out of 5 cases of FL with 1p36 deletions [44].
It is noteworthy that in 9 cases of NHL with t(14;18)(q32;q21),
the breakpoints were clustered in a region of 2.4 Mb. The most
distal commonly deleted gene in this cluster was TNFRSF9 (located
at 8.0 Mb from the 1p telomere), a gene whose expression in the
microenvironment of DLBCL was recently shown to predict
overall survival (OS) [45]. Furthermore, FISH alone (case 058) or
combined with SNP-arrays (case 142) allowed us to locate the
1p36 deletion in the same 2.4 Mb cluster in 2 cases exhibiting a
new subtype of FL [46], characterized by a predominantly diffuse
growth pattern, a frequent inguinal location, and the formation of
large, localized tumors. These tumors lack the t(14;18)(q32;q21)
and display a del(1p36) [47]. As 1p36 deletions are similar in FL
with and without typical 18q21/BCL2 translocations, it raises
questions about a common initial oncogenic event in both
subtypes of FL.
Terminal 1p36 deletions are frequent and can be underesti-
mated by conventional cytogenetics [22]. The identification of
Figure 3. Unbalanced, non-telomeric rearrangements. Each column represents a case, each line represents a BAC or fosmid probe. 2 Mb
intervals on 1p36 are represented at the same size. Diagnoses are highlighted in gold in myeloid cases and in light yellow in lymphoid cases. The
results of the used BAC probes are represented in unshadowed boxes, inferences are represented in shadowed boxes. Cells are painted green if the
probe hybridizes to the der(1), purple if the probe signal is weaker on the der(1) than on the normal chromosome 1, and red if the probe is deleted.
There was one case of interstitial deletion (case 143) that was included in this subgroup as it did not belong to any of the other two subgroups; it was
ordered according to its breakpoint on 1p36. Additional details are available in Table S3.
doi:10.1371/journal.pone.0026311.g003
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these deletions is clinically important in FL with and without
(14;18)(q32;q21), as they have been shown to be correlated not
only with shorter OS [48] but also with a higher risk of
transformation, independently of International Prognostic Index
(IPI) [33]. Furthermore, in our series, there were 1p36 deletions in
DLBCL with and without (14;18)(q32;q21), a translocation present
in up to 20% of DLBCL [49]. It would therefore be interesting to
evaluate the prognostic impact of 1p36 deletions not only in FL,
but also in DLBCL. Given the heterogeneity of breakpoints on
1p36, we suggest to use very distal BAC probes, in or near the
TNFRSF14 locus, in order to detect 1p36 deletions in FL.
In our series of cases with 1p36 aberrations, add(1)(p36) was the
most frequent abnormality. As the nature of the additional
chromosomal material was non recurrent when identifiable, with
the exception of the t(1;1)(p36;q12–23), we chose to focus on the
breakpoints on 1p36 in these cases and not to characterize the
partner loci. Among cytogenetically identified aberrations, the
most common was thus the t(1;1)(p36;q12–23) (12 cases). This
aberration was molecularly heterogeneous and breakpoints on 1p
were distributed over 19 Mb, displaying a larger dispersion than
previously described [50] (Figure 3 and Table S3). This
unbalanced rearrangement, leading to 1p36 deletion and 1q
duplication, is recurrent in NHL, with an incidence of 3–4% in the
t(14;18)(q32;q21) positive FL and DLBCL [50]. A mechanism of
homologous recombination is suspected to play a role in this
rearrangement. The t(1;1)(p36;q12–23) cases in our series were not
restricted to lymphoid malignancies as usually reported but also
seen in myeloid malignancies (50% each), raising the question of a
common oncogenic mechanism.
1p36 deletions are frequent events in hematological and non-
hematological malignancies. At the moment, no consensus tumor
suppressor gene has been identified in this region. Whether several
tumor suppressor genes are involved, or del(1)(p36) affects small
non-coding RNAs, remains elusive. Of note, miRNA hsa-mir-34a
was included in the deleted region of 18 cases with unbalanced
rearrangements, mainly B-cell lymphomas (12/18). Hsa-mir-34a is
Figure 4. Telomeric rearrangements. Schematic representation of the probes used and of the findings in the cases of telomeric rearrangements.
The sub-telomeric probe TelVysion 1p H is represented in green, the pan-telomeric probe Star*FISH in red. Material from chromosome 1 is
represented in white and the additional material is shaded. A: normal pattern; B: the sub-telomeric and pan-telomeric probes are retained in a
centromeric position to the additional material (7 cases); C: only the sub-telomeric probe is retained in a centromeric position to the additional
material (6 cases); D: the sub-telomeric probe is present and the presence of the pan-telomeric probe cannot be evaluated due to the resolution of
the FISH probes (2 cases): given the shortness of the additional material, it is impossible to assess whether the signal seen with the pan-telomeric
probe corresponds to the signal seen in all cases at the telomeric end of the derivative chromosomes, or whether it corresponds to the juxtaposition
of this telomeric signal with an intra-chromosomal signal. Additional FISH results are available in Table S4.
doi:10.1371/journal.pone.0026311.g004
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a target of p53 involved in cellular proliferation and apoptosis [6].
Its deletion has already been suggested to play a role in other B-
cell lymphoproloferations as well as in neuroblastoma [6,51].
The 15 very telomeric rearrangements identified by FISH in
our study would not have been detected by array-CGH or SNP
analysis. There were at least 7 cases with intrachromosomal
telomeric sequences. Whether these resulted from the insertion of
DNA within the very distal portion of 1p or from chromosome
fusion events between 1p and another chromosome end followed
by breakage at anaphase (breakage-fusion-bridge cycle) is
unknown. If the latter assumption were true, this would reflect
chromosomal instability, but why would chromosome fusion
events specifically happen at 1p end and not at other chromosome
ends? Although we did not detect them in our experimental
conditions, we cannot rule out the possibility that intrachromo-
somal telomeric sequences are also present on other chromosomes.
On the other hand, the hypothesis that DNA fragments would be
inserted within telomeric sequences of 1p end is in contradiction
with the well-established fact that NHEJ is normally prevented at
functional telomeres [52]. Hence, it is unclear how these
rearrangements at 1p ends occurred and whether they represent
oncogenic events or result from chromosomal instability during
oncogenesis.
In conclusion, using FISH, we characterized the breakpoints on
1p36 in 81 cases of hematological malignancies with cytogenetic
1p36 alterations not affecting the PRDM16 locus and showed that
the breakpoints were more widely distributed than previously
reported. We defined breakpoint cluster regions, especially within
or near the TP73 locus. We refined the terminal 1p36 deletions in
FL with and without t(14;18)(q32;q21). Given that 1p36 losses are
known to have a prognostic impact in FL, are cryptic in a
proportion of cases and are also detected in DLBCL, we suggest to
evaluate the prognostic impact of 1p36 deletions in B-cell
lymphomas with distal 1p36 BAC probes, independently of the
presence of a cytogenetic 1p36 rearrangement. We also found
novel partner regions on 1p36 for the known multi-partner genes
HMGA2 and RUNX1. The functional impact of the presence of
intra-chromosomal telomeric repetitive sequences is unclear.
Whether the 1p36 rearrangements are causal or associated with
disease progression remains to be studied. Further molecular and
functional studies are required to identify the targeted tumor
suppressor gene(s), especially in B-cell lymphomas.
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